Cybin announces the development of a scalable psychedelic facilitation training program, embarkct

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that it has commenced the development of a streamlined, scalable version of its embark training program, known as embarkct. the embark psychedelic facilitator training program was launched in october 2021 and provides facilita.
CYBN Ratings Summary
CYBN Quant Ranking